---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-152309"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:48:53.531350+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Summit raises $200M, expands ivonescimab license to LAMEA regions

## Summary
- Raised $200M via private placement of 22.2M shares at $9.00/share, a premium to the prior close.
- Expanded ivonescimab license territory to Latin America, Middle East, Africa; $15M upfront plus up to $55M milestones.
- Net proceeds will fund ivonescimab clinical development and general corporate purposes.
- Registration rights agreement filed; resale registration statement expected within 60 days of closing.
- Amendment strengthens data-sharing provisions for global ivonescimab trials.

## SEC filing metadata
- accession: 0001193125-24-152309
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000119312524152309/0001193125-24-152309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000119312524152309/d768276d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-152309
- JSON: https://secwatch.observer/filing/0001193125-24-152309.json
- Plain text: https://secwatch.observer/filing/0001193125-24-152309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.